Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter study of HBV-specific cytotoxic T lymphocyte adoptive therapy for chronic hepatitis B
ChiCTR1800018850Phase 2Not yet recruiting
- Sponsor
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Start
- Nov 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of interferon alfa in Chronic Hepatitis B (CHB) (3 arms), sponsored by Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine. Primary endpoints: HBsAg, HBeAg and 3 more. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
interferon alfa
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1800018850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018850.